<div id="readability-page-1"><div><p>Denali Therapeutics (DNLI) stock has been in focus after the company and Biogen halted the Phase 2b LUMA trial of BIIB122 for idiopathic Parkinson’s disease, following missed primary and secondary efficacy endpoints.</p> <p>For investors, attention now shifts to Denali’s planned independent Phase 2a BEACON trial in genetically targeted Parkinson’s patients. This keeps BIIB122 in the pipeline but with a narrower, more focused development path.</p> <p>See our latest analysis for Denali Therapeutics.</p> <p>At a share price of $21.66, Denali’s short term momentum has been strong, with a 1 week share price return of 10.96% and year to date share price return of 33.13%. However, the 3 year total shareholder return has declined 30.22% and the 5 year total shareholder return has declined 70.62%, pointing to renewed interest after a difficult longer period.</p> <p>If this kind of biotech volatility has your attention, it can be useful to see how other healthcare related AI developers are trading right now using the 40 healthcare AI stocks.</p> <p>With Denali shares at $21.66, a value score of 1, and trading at a reported 57% discount to the average analyst price target, you have to ask whether this is a mispriced recovery story or whether the market is already factoring in all realistic upside.</p> <h2>Price to Book of 3.7x: Is it justified?</h2> <p>Denali is trading on a P/B of 3.7x, which screens as good value versus its own peer set average of 7.4x, but looks expensive against the broader US biotech industry at 2.3x.</p> <p>P/B compares the company’s market value to its net assets on the balance sheet. This measure is often used for pre profit biotechs where earnings and revenue are not yet meaningful. For a research heavy company with very low reported revenue and ongoing losses, this kind of asset based yardstick can help you see how much investors are paying for the pipeline and intellectual property relative to book value.</p> <p>The split signals two different reference points. Against its immediate peers, the 3.7x P/B suggests the market is assigning a lower valuation relative to book than the 7.4x peer average. That can indicate more cautious expectations on Denali’s path to monetising its programs. Against the wider US biotech industry, however, the same 3.7x sits above the 2.3x average, which implies investors are still willing to pay more per dollar of book value than for many smaller or less research intensive biotechs.</p> <p>There is currently insufficient data to calculate a P/B fair ratio, so there is no regression based anchor that indicates where this multiple could gravitate over time. Instead, the comparison rests on how you weigh Denali’s pipeline potential against its lack of current profitability and very low reported revenue.</p> <p>See what the numbers say about this price — find out in our valuation breakdown.</p> <p><strong>Result: Price to book of 3.7x (ABOUT RIGHT)</strong></p> <p>However, the story can quickly change if further BIIB122 data disappoints again or if continued losses of US$508.017 million strain confidence in the pipeline.</p> <p><strong>Wall Street's queuing for one rocket.</strong> While SpaceX counts down to its IPO, other companies tied to the new space race are already in orbit. → 20 Compelling Space Companies watchlist · Global Space Race Investing Ideas screener · Scan the sector by valuation on Rocket Lab's valuation page.</p> <h2>Another view on fair value</h2> <p>The P/B of 3.7x might look roughly in line with expectations, but the SWS DCF model points in a different direction. On this view, Denali at $21.66 is above an estimated future cash flow value of $16.59, which raises the question of how much execution risk you are really being paid for.</p> <p>Look into how the SWS DCF model arrives at its fair value.</p> <figure><img height="476" src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/503ac71f-53d0-4f99-abee-37f82bbdd2c8/chart/dcf/query-ZGF0ZT0yMDI2LTA2LTEz?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="746" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/503ac71f-53d0-4f99-abee-37f82bbdd2c8/chart/dcf/query-ZGF0ZT0yMDI2LTA2LTEz"/><figcaption>DNLI Discounted Cash Flow as at Jun 2026</figcaption></figure><p>Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Denali Therapeutics for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 44 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.</p> <h2>Next Steps</h2> <p>With sentiment in this article mixed between recent momentum and pipeline uncertainty, it makes sense to look at the full picture yourself and move quickly to form an independent view. To see how potential upside stacks up against the issues investors are worried about, start by reviewing the 1 key reward and 2 important warning signs.</p> <h2>Looking for more investment ideas?</h2> <p>Denali might be on your radar now, but your next strong opportunity could be sitting elsewhere if you do not widen the field with a few targeted stock screens.</p> <ul> <li>Target potential bargains that combine quality with attractive pricing by running the 44 high quality undervalued stocks.</li> <li>Strengthen the core of your portfolio by checking companies highlighted in the solid balance sheet and fundamentals stocks screener (48 results).</li> <li>Get ahead of the crowd by scanning the screener containing 20 high quality undiscovered gems before everyone else starts paying attention.</li> </ul> <p><em> This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data         and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your         financial situation. We aim to bring you long-term focused analysis driven by fundamental data.         Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.         Simply Wall St has no position in any stocks mentioned.</em></p><div><h3><strong>New: </strong>Manage All Your Stock Portfolios in One Place</h3><p>We've created the <strong>ultimate portfolio companion</strong> for stock investors, <strong>and it's free.</strong></p><p>• Connect an unlimited number of Portfolios and see your total in one currency<br/>• Be alerted to new Warning Signs or Risks via email or mobile<br/>• Track the Fair Value of your stocks<br/></p><p>Try a Demo Portfolio for Free</p></div></div></div>

DNLI

<p>Denali Therapeutics (DNLI) stock faces scrutiny after halting the Phase 2b LUMA trial for BIIB122 due to missed efficacy endpoints. Attention shifts to the focused Phase 2a BEACON trial. Despite recent short-term momentum, long-term returns have declined. Valuation analysis shows a P/B of 3.7x, considered good value against peers but expensive versus the broader biotech industry. A DCF model suggests the current price is above fair value, highlighting execution risks and pipeline uncertainty.</p>

Simplywall

Denali Therapeutics (DNLI) Stock Valuation After Setback In LUMA Trial And Focus On BEACON Study